Overview

Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

The present study is a multicenter, prospective phase II-study to evaluate the chronic GvHD and progression-free survival at 2 years after after allogeneic stem cell transplantation for patients with multiple myeloma.

Phase:

Phase 2

Details

Lead Sponsor:

Universitätsklinikum Hamburg-Eppendorf

Collaborators:

Clinical Trial Center North (CTC North GmbH & Co. KG)
CTC North (CRO)
Riemser

Treatments:

Cyclophosphamide